RT Journal Article
SR Electronic
T1 Genome-wide characterization of 54 urinary metabolites reveals molecular impact of kidney function
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.20.23300206
DO 10.1101/2023.12.20.23300206
A1 Valo, Erkka
A1 Richmond, Anne
A1 Mutter, Stefan
A1 Campbell, Archie
A1 Porteous, David
A1 Wilson, James F
A1 ,
A1 Groop, Per-Henrik
A1 Hayward, Caroline
A1 Sandholm, Niina
YR 2023
UL http://medrxiv.org/content/early/2023/12/21/2023.12.20.23300206.abstract
AB Dissecting the genetic mechanisms underlying urinary metabolite concentrations can provide molecular insights into kidney function and open possibilities for causal assessment of urinary metabolites with risk factors and disease outcomes. Proton nuclear magnetic resonance metabolomics provides a high-throughput means for urinary metabolite profiling, as widely applied for blood biomarker studies. Here we report a genome-wide association study meta-analysed for 3 European cohorts comprising 8,026 individuals, covering both people with type 1 diabetes and general population settings. We identified 52 associations (p<9.3×10-10) for 19 of 54 studied metabolite concentrations. Out of these, 32 were not reported previously for relevant urinary or blood metabolite traits. Subsequent two-sample Mendelian randomization analysis suggests that estimated glomerular filtration rate (eGFR) causally affects 13 urinary metabolite concentrations whereas urinary ethanolamine, an initial precursor for phosphatidylcholine and phosphatidylethanolamine, was associated with higher eGFR lending support for a potential protective role.Competing Interest StatementP-HG has served on advisory boards for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk, Sanofi, and has received lecture honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk PeerVoice, and Sanofi. P-H G has also received investigator-initiated grants from Eli Lilly and Roche.Funding StatementThe research in FinnDiane study was supported by funding from Folkhälsan Research Foundation, Wilhelm and Else Stockmann Foundation, Liv och Hälsa Society, Helsinki University Hospital Research Funds (EVO TYH2018207), Academy of Finland (299200, and 316664), Novo Nordisk Foundation (NNF OC0013659, NNF23OC0082732), Sigrid Jusélius Foundation, and Finnish Diabetes Research Foundation. Genotyping of the FinnDiane GWAS data was funded by the Juvenile Diabetes Research Foundation (JDRF) within the Diabetic Nephropathy Collaborative Research Initiative (DNCRI; Grant 17-2013-7), with GWAS quality control and imputation performed at University of Virginia. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z). The Viking Health Study - Shetland (VIKING) was supported by the MRC Human Genetics Unit quinquennial programme grant "QTL in Health and Disease".Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The FinnDiane study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District (491/E5/2006, 238/13/03/00/2015, and HUS-3313-2018, July 3rd, 2019) and the participants gave their informed consent before recruitment. The FinnDiane study was performed following the Declaration of Helsinki. All the Viking Health Study - Shetland (VIKING) participants gave informed consent and the study was approved by the South East Scotland Research Ethics Committee, NHS Lothian (reference: 12/SS/0151). The VIKING study was performed in accordance with the Declaration of Helsinki. All the GS:SFHS participant gave informed consent and the ethical approval for the study was obtained from the Tayside Committee on Medical Research Ethics (on behalf of the National Health Service, reference 05/S1401/89). The GS:SFHS study was performed in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes